Chronic Pulmonary Aspergillosis—Where Are We? and Where Are We Going?

    Research output: Contribution to journalArticlepeer-review

    7 Downloads (Pure)


    Chronic pulmonary aspergillosis (CPA) is estimated to affect 3 million people worldwide making it an under recognised, but significant health problem across the globe, conferring significant morbidity and mortality. With variable disease forms, high levels of associated respiratory co-morbidity, limited therapeutic options and prolonged treatment strategies, CPA is a challenging disease for both patients and healthcare professionals. CPA can mimic smear-negative
    tuberculosis (TB), pulmonary histoplasmosis or coccidioidomycosis. Cultures for Aspergillus are usually negative, however, the detection of Aspergillus IgG is a simple and sensitive test widely used in diagnosis. When a fungal ball/aspergilloma is visible radiologically, the diagnosis has been made
    late. Sometimes weight loss and fatigue are predominant symptoms; pyrexia is rare. Despite the efforts of the mycology community, and significant strides being taken in optimising the care of these patients, much remains to be learnt about this patient population, the disease itself and the best use
    of available therapies, with the development of new therapies being a key priority. Here, current knowledge and practices are reviewed, and areas of research priority highlighted.
    Original languageEnglish
    JournalJournal of Fungi
    Issue number18
    Publication statusPublished - 7 Jun 2016


    Dive into the research topics of 'Chronic Pulmonary Aspergillosis—Where Are We? and Where Are We Going?'. Together they form a unique fingerprint.

    Cite this